| 2026-02-23 |
QurAlis Corporation |
Results QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS quralis.com ↗
Results from this study demonstrated QRL-201 had an effect on disease progression in ALS patients; this effect was confirmed by markers of clinical efficacy and changes in a clinically relevant biomarker, along with target engagement. |
| 2024-11-19 |
QurAlis Corporation |
Results QurAlis’ ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed quralis.com ↗
PK data analysis in dose-escalation phase indicated exposures of QRL-201 met or exceeded the targeted therapeutic range prompting advancement to the DRF phase |
| 2023-07-11 |
QurAlis Corporation |
Regulatory QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS quralis.com ↗
|
| 2023-06-06 |
QurAlis Corporation |
Regulatory QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS quralis.com ↗
|
| 2022-12-08 |
QurAlis Corporation |
Regulatory QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS quralis.com ↗
|
| 2021-12-06 |
QurAlis Corporation |
Results QurAlis Presents New Data Confirming Role of STATHMIN-2 in Neuronal Disease Biology at 32nd International Symposium on ALS/MND quralis.com ↗
New research connecting function of STATHMIN-2, TDP-43, and ALS cell biology further validates QRL-201, Company’s lead development candidate in ALS |